Maze Therapeutics (NASDAQ:MAZE) SVP Amy Bachrodt Sells 5,000 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) SVP Amy Bachrodt sold 5,000 shares of the stock in a transaction dated Tuesday, December 30th. The stock was sold at an average price of $40.08, for a total transaction of $200,400.00. Following the sale, the senior vice president directly owned 12,965 shares in the company, valued at approximately $519,637.20. This represents a 27.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Amy Bachrodt also recently made the following trade(s):

• On Monday, December 29th, Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.58, for a total transaction of $405,800.00.

Maze Therapeutics Stock Up 3.4%

MAZE stock traded up $1.38 during trading on Wednesday, hitting $41.43. The company had a trading volume of 394,842 shares, compared to its average volume of 325,768. The firm has a 50-day moving average price of $36.34 and a 200-day moving average price of $24.46. Maze Therapeutics, Inc. has a 12 month low of $6.71 and a 12 month high of $43.29. The stock has a market cap of $1.99 billion and a price-to-earnings ratio of -1.98.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.08.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds have recently bought and sold shares of the company. Woodline Partners LP boosted its position in shares of Maze Therapeutics by 10.0% during the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after purchasing an additional 94,529 shares in the last quarter. XTX Topco Ltd bought a new position in Maze Therapeutics during the third quarter worth about $697,000. Susquehanna International Group LLP grew its stake in Maze Therapeutics by 53.0% in the third quarter. Susquehanna International Group LLP now owns 16,165 shares of the company’s stock valued at $419,000 after acquiring an additional 5,598 shares during the period. Parkman Healthcare Partners LLC acquired a new stake in shares of Maze Therapeutics during the third quarter worth about $5,186,000. Finally, Nantahala Capital Management LLC bought a new position in shares of Maze Therapeutics during the 3rd quarter valued at about $2,421,000.

Wall Street Analysts Forecast Growth

MAZE has been the subject of several analyst reports. Wells Fargo & Company assumed coverage on shares of Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price target for the company. HC Wainwright raised their price objective on shares of Maze Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, December 3rd. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. BTIG Research upped their target price on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Finally, Guggenheim restated a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research report on Friday, December 19th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $43.38.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.